They also reported that (2) IFN-β produced by regressor tumors drive the ISG+ cDC2 state via MHC-I dressing and costimulatory molecule activation (CD40, CD80, and CD86), activate tumor-reactive CD8+ T cells, and rescue anti-tumor immunity against progressor tumors. Here, CD86 is linked to neoplasm.